Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
Gyre Therapeutics announced its second quarter 2026 financial results, reporting Q2 revenue of $29.1 million and a GAAP basic loss per share of $0.12. The company affirmed its full-year 2026 revenue guidance of $100.5 to $111.0 million. Key business updates include the acceptance of the NDA for F351 (hydronidone) for chronic hepatitis B-induced liv…